Prospective randomized controlled study to determine the effect of topical application of botulinum toxin A for crow's feet after treatment with ablative fractional CO2 laser
Recommended Citation
Mahmoud BH, Burnett C, Ozog DM. Prospective randomized controlled study to determine the effect of topical application of botulinum toxin A for crow's feet after treatment with ablative fractional CO2 laser. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 2015; 41 Suppl 1:75-81.
Document Type
Article
Publication Date
1-1-2015
Publication Title
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
Abstract
BACKGROUND: Botulinum toxin Type A (BoNT A) for the treatment of facial wrinkles is delivered through local injection. We previously demonstrated that topical surface application of BoNT A has negligible cutaneous bioavailability and is not effective in treating wrinkles.
OBJECTIVE: To determine the effect of BoNT A solution applied topically on the skin surface immediately after ablative fractional CO2 laser treatment.
METHODS: We conducted a randomized controlled trial for patients with periorbital wrinkles (crow's feet) (n = 10). Treatment was performed on both sides of the face with fractional ablative CO2 laser followed by the application of topical solutions of BoNT A on one side and normal saline as control on the other side. Pretreatment assessment was performed, and at 1 and 4 weeks after treatment.
RESULTS: There was a clinically significant greater degree of improvement in wrinkles after treatment with CO2 laser, on the topically applied BoNT A side. Also, the difference between the 2 treatment types (laser followed by topical BoNT A vs laser followed by saline) at 1 week and at 1 month was statistically significant.
CONCLUSION: Topically, noninjectable form of BoNT A applied on the surface of the skin after ablative fractional CO2 laser is effective in the treatment of lateral periorbital wrinkles.
Medical Subject Headings
Administration, Cutaneous; Adult; Aged; Botulinum Toxins, Type A; Combined Modality Therapy; Edema; Erythema; Eye; Facial Dermatoses; Female; Humans; Lasers, Gas; Male; Middle Aged; Neuromuscular Agents; Pain; Patient Satisfaction; Prospective Studies; Skin Aging
PubMed ID
25548849
Volume
41 Suppl 1
First Page
75
Last Page
81
